Disease or Syndrome
FDA Sets Efficacy Threshold for Obesity Therapies Amid Market Expansion
FDA, obesity therapies, weight-loss treatments, efficacy standards, obesity market trends
Marea Therapeutics Announces Breakthrough Phase II Results for MAR001, a Novel Monoclonal Antibody Targeting Remnant Cholesterol
Marea Therapeutics, MAR001, Remnant Cholesterol, Monoclonal Antibody, Cardiovascular Disease, ANGPTL4, Phase II Clinical Trial
Denali Therapeutics Faces Another Setback in ALS Treatment Development
Denali Therapeutics, ALS, Phase II/III trial, HEALEY ALS Platform trial, DNL343, treatment failure
Bausch + Lomb Enters Strategic Collaboration with City Therapeutics for RNAi-Based Eye Disease Treatment
Bausch + Lomb, City Therapeutics, RNAi, eye disease, geographic atrophy, age-related macular degeneration, strategic collaboration
Intellia Therapeutics Slashes Workforce by 27% to Focus on Late-Stage CRISPR Candidates Amid Challenging Market Environment
Intellia Therapeutics, CRISPR, Workforce reduction, Late-stage drug candidates, NTLA-2002, Nexiguran ziclumeran (nex-z), Hereditary angioedema, Transthyretin (ATTR) amyloidosis, Commercialization strategy
IGM Biosciences Halts Autoimmune Projects Amid Layoffs Following Disappointing Trial Data
IGM Biosciences, layoffs, autoimmune diseases, bispecific antibody T cell engagers, imvotamab, IGM-2644, biotech industry
Eli Lilly and Alchemab Therapeutics Collaborate on Novel ALS Therapies
Eli Lilly, Alchemab Therapeutics, ALS, Therapeutic Antibodies, Neurodegenerative Disease, Drug Development
Mendaera Appoints Eric Davidson as Chief Commercial Officer to Lead Handheld Medical Robot Launch
Mendaera, handheld medical robot, chief commercial officer, Eric Davidson, medical robotics, AI, interventional radiology
Novo Nordisk and Lilly Lead Clarivate’s 2025 ‘Drugs to Watch’ List with Breakthrough Therapies
Clarivate, Drugs to Watch 2025, Novo Nordisk, Eli Lilly, Obesity treatments, Gene therapy, Oncology, Blockbuster drugs, Pharmaceutical industry
Sana Biotechnology’s Revolutionary Type 1 Diabetes Therapy Triggers Stock Surge
Sana Biotechnology, Type 1 Diabetes, Immune-Evading Therapy, Stock Surge, Hypoimmune Technology